Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 2Phase 2/3 1

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2Thoracic 1Dermatologic 1

Conditions

Melanoma 17Neoplasms 11Neoplasm Metastasis 4Thyroid Carcinoma, Anaplastic 2Multiple Myeloma 2Brain Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Thyroid Neoplasms 1Thrombocytosis 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Colorectal Neoplasms 1

Interventions

dabrafenib 2Trastuzumab 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tremelimumab 1trametinib 1tipifarnib 1mercaptoundecahydrododecaborate 1durvalumab 1cemiplimab 1Semaxinib 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Paclitaxel 1PLX8394 1Interleukin-12 Subunit p35 1Interleukin-12 1Docetaxel 1Adalimumab 14-boronophenylalanine-fructose 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Thyroid Carcinoma, Anaplastic × dabrafenib × Clear all
NCT03975231 2026-04-08

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

City of Hope Medical Center

Phase 1 Recruiting
6 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT04418167 2025-09-03

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

JS InnoPharm, LLC

Phase 1 Suspended
71 enrolled
DermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡